CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Amgen AMGN

Verkoop
 Koop

Amgen live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Tommy Yap 2025 Mar 22, 16:00

Week Ahead: Investor Eyes on U.S. Inflation & Core PCE for Fed’s Next Move

Forex Indices
Frances Wang 2025 Mar 20, 16:00

Stock indices news: US stock indices rose on Fed decision

Indices
Tommy Yap 2025 Mar 20, 16:00

Morning Note: Oil Sanctions, Canada Data, Ripple's Space Gamble

Morning Note Oil Forex
Frances Wang 2025 Mar 19, 16:00

US stock indices update: NASDAQ 100, Dow Jones 30 and S&P 500 Forecast

Indices
Tommy Yap 2025 Mar 19, 16:00

Morning Note: SNB Rate Cut Expected, BoE Decision & Accenture Earnings in Focus

Morning Note Forex
Frances Wang 2025 Mar 18, 16:00

Stock market today: NASDAQ Index, SP500, Dow Jones Forecasts

Stocks
Tommy Yap 2025 Mar 18, 16:00

Morning Note: BoJ Holds Rates, Fed Decision Looms & Tencent Earnings in Focus

Morning Note BoJ Fed
Frances Wang 2025 Mar 17, 16:00

Stock market today: Dow, S&P 500, Nasdaq remain steady on tariff tension

Stocks Indices

Info

Spread

2.39

Spread (%)

0.7595 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Maandag

13:31 - 19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Donderdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

169778266112

Uitstaande aandelen

537204992

Datum winstcijfer (volgende)

1999-11-22

Div. rend.

2025-06-06

Ex-dividenddatum

2025-05-16

Jaarlijks verwachte dividendpercentage

9.52

Jaarlijks verwachte dividendrendement

0.0301

Winst per aandeel

7.55

Meer informatie over dit instrument

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten
Trustpilot